CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 6, 2020
Result type: Reports
Project Number: SR0648-000
Product Line: Common Drug Review

Generic Name: etonogestrel

Brand Name: TBC

Manufacturer: Merck Canada Inc.

Indications: Prevention of pregnancy

Manufacturer Requested Reimbursement Criteria1: ​For the prevention of pregnancy as an open benefit without restrictions.

Submission Type: New

Project Status: Pending

Call For Patient Input: May 6, 2020

Patient Input Closed: June 25, 2020

Anticipated Date: June 3, 2020

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback